Attention is turning to the vaccines that most developed countries are relying on to control the COVID-19 pandemic, asking two key questions: will the existing vaccines work against Omicron and, iIf not, how quickly can manufacturers ‘tweak’ them to boost their efficacy?
In the last few days, Pfizer-BioNTech, Moderna and Johnson & Johnson have all announced that they have begun work on Omicron-specific versions of their existing vaccines.
